| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -5,972 | -4,495 | -7,508 | - |
| Income tax expense | 0 | 0 | 715 | - |
| Net loss | -5,972 | -4,495 | -8,223 | -7,688 |
| Unrealized gain on available-for-sale investments | - | - | - | 6 |
| Other comprehensive income (loss), tax | - | - | - | 7,682 |
| Net loss per share of common stock - basic | -1.14 | -0.06 | -0.11 | -0.1 |
| Net loss per share of common stock - diluted | -1.14 | -0.06 | -0.11 | -0.1 |
| Weighted average shares outstanding - basic | 5,233,981 | 77,844,055 | 76,921,843 | 74,745,415 |
| Weighted average shares outstanding - diluted | 5,233,981 | 77,844,055 | 76,921,843 | 74,745,415 |
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. (CLSD)